18:45-20:15

Plenary 2: Regulatory & Manufacturing

Chair: Juan Ruiz, Forge Therapeutics

18:45    Marcos Timon, AEMPS

INV23   Regulatory considerations for ATMP development

19:15    Cesar Trigueros, Viralgen

INV24    AAV serotype associated impurities under a production platform

ABSTRACT >

19:45    Julio Delgado, IDIBAPS, Barcelona  ⓘ

INV25   Development of academic CART-cell products in Europe: is it possible?